Who are Leuprolide acetate - Formulation A's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lupron, Micronor, COS with GnRH antagonists and HP-HMG, Gonapeptyl®, Cetrorelix and Leuprolide, Zoladex and Casodex.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/leuprolide-acetate-formulation-a.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Leuprolide acetate - Formulation A — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Leuprolide acetate - Formulation A (Leuprolide acetate - Formulation A) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GnRH agonist. Area: Oncology; Endocrinology.

phase 3 GnRH agonist GnRH receptor Oncology; Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Leuprolide acetate - Formulation A (Leuprolide acetate - Formulation A) — Abbott. Leuprolide acetate is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased testosterone and estrogen production.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Leuprolide acetate - Formulation A TARGET	Leuprolide acetate - Formulation A	Abbott	phase 3	GnRH agonist	GnRH receptor
Lupron	leuprorelin	Accord Healthcare S.L.U.	marketed	Gonadotropin Releasing Hormone Receptor Agonist	GnRH receptors	1985-01-01
Micronor	norethisterone	Johnson & Johnson	marketed	Progestin	GnRH receptors	1962-01-01
COS with GnRH antagonists and HP-HMG	COS with GnRH antagonists and HP-HMG	Instituto Valenciano de Infertilidad, IVI VALENCIA	marketed	Gonadotropin protocol / Assisted reproductive technology regimen	GnRH receptor (antagonism); FSH receptor and LH receptor (agonism via exogenous gonadotropins)
Gonapeptyl®	Gonapeptyl®	University Hospital, Ghent	marketed	GnRH agonist	GnRH receptor
Cetrorelix and Leuprolide	Cetrorelix and Leuprolide	Instituto Valenciano de Infertilidad, IVI VALENCIA	marketed	GnRH antagonist and GnRH agonist combination	GnRH receptor
Zoladex and Casodex	Zoladex and Casodex	AstraZeneca	marketed	GnRH agonist (Zoladex) and androgen receptor antagonist (Casodex)	GnRH receptor (Zoladex); androgen receptor (Casodex)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-03-22 — Lupron · 9617303 · US
2031-02-05 — Lupron · 8921326 · US

Sponsor landscape (GnRH agonist class)

Takeda · 4 drugs in this class
Abbott · 3 drugs in this class
Ipsen · 3 drugs in this class
Changchun GeneScience Pharmaceutical Co., Ltd. · 3 drugs in this class
University of Pisa · 2 drugs in this class
Chong Qing Reproducive and Genetic Institute · 1 drug in this class
Chesapeake Urology Research Associates · 1 drug in this class
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
Enteris BioPharma Inc. · 1 drug in this class
Colorado Center for Reproductive Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Leuprolide acetate - Formulation A — Competitive Intelligence Brief. https://druglandscape.com/ci/leuprolide-acetate-formulation-a. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing